Clinical trial
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With…
NCT00493805 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00493805 |
|---|---|
| Title | Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) |
| Official title | Study to Evaluate Response Rates in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic, Insulin Resistance |
| Intervention type | Drug |
| Interventions | Combination of pegylated interferon alfa-2b and ribavirin |
| Enrollment | 59 |
| Start date | Apr 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jun 28, 2007 |
| Last update posted | Apr 7, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: